91. Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease

P700
Corticosteroid (CS) therapy does not influence immune reactivity in patients with non-specific interstitial pneumonia (NSIP)
Anna Zaytseva, Evgenij Shmelev, Vladislav Gergert. Granulomatosis Lung Diseases, Central Tuberculosis Research Institute, Moscow, Russian Federation

Aim. To assess the influence of CS therapy on immune reactivity in patients with NSIP.

Patients and methods. 27 patients (8 male 19 female, average age 57.3 ± 2.3 yrs) with histologically proved NSIP were included. In 11 patients of group 1 the diagnosis was recently established and treatment was not yet started. 16 patients of group 2 received CS during 2-10 yrs. Blood level of IL-1β, IL-2, IL-8, TNF-α basal and after FGA stimulation was assessed by solid-phase immune-enzyme assay. CD20, CD4, CD8, CD3, CD16 in blood were detected by means of monoclonal antibodies.

Results. Basal IL-1, IL-2 and TNF were increased (171.0 ± 55.5 pg/ml, 14.5 ± 3.2 pg/ml, 101.3 ± 43.3 pg/ml, correspondingly) and basal level of IL-8 was normal (777.8 ± 140.8 pg/ml) in patients of group 1. In patients of group 2 basal IL-2 (16.3 ± 2.7 pg/ml) and TNF (86.4 ± 40.6 pg/ml) were increased and IL-1 (62.1 ± 21.6 pg/ml), IL-8 (590.4 ± 127.0 pg/ml) were normal. IL-1, IL-2, IL-8, TNF levels after stimulation were not increased in patients of both groups. There was no difference of CD20, CD4, CD8, CD3, CD16 cells quantity in patients of both groups.

Conclusions. Continuous treatment by low doses of corticosteroids does not influence immune reactivity in patients with NSIP.

P701
Does emphysema influence the application of du Bois score in idiopathic pulmonary fibrosis?
Aline Bodlet1, Luc Delaunois 1, Caroline Dahlqvist 1, Jacques Jamart2, Gisèle Maury1. 1Pneumology, CHU Mont-Godinne, Yvoir, Belgium; 2USS, CHU Mont-Godinne, Yvoir, Belgium

Idiopathic pulmonary fibrosis (IPF) is the most frequent interstitial pulmonary fibrosis. Development in CT scan technology improved accuracy in lung study. Emphysema can be associated to IPF; the most common form is the “Combined pulmonary fibrosis and emphysema” syndrome (CPFE). The aim of this retrospective cohort study was to assess the impact of emphysema associated to IPF on functional parameters (Forced Vital Capacity FVC and Total Lung Capacity TLC) at baseline (t0) and on the loss of FVC after 6 months (t6) which is used in the du Bois prognostic score.

Abstract printing supported by Chiesi. Visit Chiesi at Stand B2.10
Thematic Poster Session

P702
Telomerase expression in idiopathic pulmonary fibrosis (IPF) and non small cell lung cancer (NSCLC)

Katerina Samara1, 2, Ioannis Giannarakis1, Maria Velivassaki1, Anna Psaraki2, Nikolaos Siafakas1, 2

1Department of Thoracic Medicine, Medical School, University of Crete, Heraklion, Crete, Greece; 2Laboratory of Molecular and Cellular Pulmonology, Medical School, University of Crete, Heraklion, Crete, Greece

Rationale: Telomeres protect chromosome ends since chromosomes lacking telomeres undergo fusion, rearrangement and translocation. Telomerase dysfunction has been linked with pathologic autoimmune responses and could play a role in both fibroinogenesis and carcinogenesis. We aim to evaluate telomerase expression (mRNA levels of both subunits TERT and TERC) in Bronchoalveolar Lavage Fluid (BALF) and lung tissue of patients with NSCLC and IPF, since there are indications of common pathogenic pathways in both diseases.

Methods: We prospectively studied 44 BALF samples from NSCLC patients, 29 BALF samples from IPF patients and 13 BALF samples from control subjects. We also studied lung tissue samples from 32 IPF patients, 10 NSCLC patients and 21 control subjects. We measured mRNA expression for both TERT and TERC by Real-Time RT-PCR.

Results: (a) Lung tissue: IPF mRNA TERT levels (0.24±0.14) were significantly lower compared to controls (0.46±0.30) (p=0.030), TERC mRNA levels were higher in the control group (4.3±1.9) compared to NSCLC (2.87±1.51) and IPF (1.21±0.97), with strong grouped statistical significance (p<0.0001). (b) BALF: TERT expression was higher in the control group (0.78±0.60) compared to IPF (0.39±0.14) and NSCLC (0.34±0.20) (p=0.005). TERC expression was higher in the IPF group (1.09±0.39) compared to controls (0.54±0.40) and NSCLC (0.62±0.19), with no grouped statistical significance.

Conclusions: Reduced expression of both telomerase subunits measured in NSCLC and IPF patients when compared to controls, suggests that telomerase genes may play a significant role in fibroinogenesis and carcinogenesis, supporting the hypothesis of a common pathway.

P703
Specific features of pulmonary mechanics and gas exchange in patients with histiocytosis X (HX)

Marina Kameneva1, Natalia Korzina1, Olga Yuryeva2, Artem Tishkov3

1Institute of Pulmonology, Pavlov's State Medical University, St. Petersburg, Russian Federation; 2Department of Physics, Mathematics and Informatics, Russian State University of Information Technology, Economics and Management, Moscow, Russian Federation; 3Internal Medicine, Ardabil University of Medical Sciences, Ardabil, Islamic Republic of Iran

Aim: To assess the changes of pulmonary mechanics and gas exchange parameters, which are typical for histiocytosis X.

Materials and methods: 67 patients with HX have been examined, including 4 men (mean age 29.1±4.8 years) and 19 women (mean age 27.1±6.2 years). Spirometry, bodyplethysmography, compliance measurement, diffusion capacity (DLCO) and blood gases were carried out for all patients.

Results: For either men or women the mean values of the lung mechanics parameters didn’t overstep the bounds of normal value, except for DLCO. Excluding 39 patients with normal value of indices, two groups of patients were identified. The first group of 20 patients shown signs of airflow limitation: decrease of the forced exhalation FEV1 (59.7±5.5%Pred) and FEV1/FVC (59.7±8.9%Pred) and diffusion normal TLC (98±6.5%Pred) by obstructive type (RV/TLC = 168.0±11.2%Pred). The second group contained 8 patients with restrictive respira-

tory pattern: reduction of TLC (70.4±2.5%Pred) and VC (71.9±4.0%Pred) without airflow limitation. Increase of pulmonary tissue retraction index (0.62±0.10 and 0.92±0.10 kPa/l) in both groups was an interesting finding. DLCO has reduced in both groups (51.4±4.2% and 56.8±6.5%Pred), but the DLCO/WA (61.0±8.2% and 70.7±4.5%Pred) has been reduced in a greater degree in patients of the first group.

Conclusions: DLCO decrease is characteristic for HX patients. Changes of lung mechanics parameters are observed much rarer. When it is the case, the obstructive pattern dominates restrictive one. In contrast to COPD, the obstructive pattern in HX is combined with increase of pulmonary tissue elasticity.

P704
The EDD (exer, DLco, dyspnea) index in diffuse systemic sclerosis with pulmonary fibrosis

Shahrzad Mohammadzadeh Lari1,2, Jaleh Shariatii2,1, Pouya Nazari2, Hassan Ghobad Marallu1,3, Seid Ali Khalghi1,2

1Lung Disease & TB Research Center, Mashhad University of Medical Sciences, Mashhad, Islamic Republic of Iran; 2Rheumatologic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Islamic Republic of Iran; 3Internal Medicine, Ardabil University of Medical Sciences, Ardabil, Islamic Republic of Iran

Introduction: Pulmonary fibrosis secondary to systemic sclerosis (SSc) is the major cause of morbidity and mortality in these patients. The aim of this study was to determine the correlation of important lung function parameters with chest high resolution CT scan (HRCT).

Methods and materials: Thirty-two consecutive diffuse SSc patients (according to the criteria of american college of rheumatology) with pulmonary involvement were enrolled in this cross-sectional study. Patients with pulmonary fibrosis secondary to other reasons, previous restrictive lung disease, and history of smoking were excluded. Complete lung function test was performed. The severity of dyspnea was evaluated by Modified Medical Research Council (MMRC) scale. EDD index was calculated based on 6MWT, DLco, and MMRC.

The EDD index in scleroderma lung fibrosis

<table>
<thead>
<tr>
<th>EDD Index</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>6MWT</td>
<td>≥350</td>
<td>250–349</td>
<td>150–249</td>
<td>&lt;150</td>
</tr>
<tr>
<td>DLco</td>
<td>≥80%</td>
<td>60–79%</td>
<td>40–59%</td>
<td>&lt;40%</td>
</tr>
<tr>
<td>MMRC</td>
<td>0–1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
</tbody>
</table>

The chest HRCT was performed and the Warrick score recorded in all patients. Results: The mean age of the patients was 39.18 years (±9.39 (SD).Seventeen (53%) of patients were in EDD stage 1 (score <25%Pred), 9 patients (28%) in stage 2 (>25% and ≤40%Pred), and 4 patients (12%) in stage 3 (<40%Pred). Warrick score was 10.84±6.94 (SD). There was statistically significant correlation between EDD index and Warrick score (p=0.001, r=0.72). Also there was statistically significant relation in EDD stages with Warrick scores (p=0.002).

Conclusion: The EDD as a useful lung function index is completely related to chest HRCT findings in SSc pulmonary fibrosis and can be used in clinical practice.

P705
Increased exhaled nitric oxide precedes lung fibrosis in a murine model of systemic sclerosis

Shong Hua Huy1,2, Shahn Le Dong1,3, Jieh Shuai1, Lui Yuen1,4, Yihua Bei1,4, Sébastien Rivière1–2, Kiet–Phong Tiev1,2, Carole Nicco3, Frédéric Batteux3,5, Anh Tuan Doi–Xuan1,6

1Pulmonary Pathology, Paris Descartes University, Paris, France; 2Immunology, Paris Descartes University, Paris, France; 3Laboratory of Immunology, Paris Descartes University, Paris, France

Background: Exhaled nitric oxide (eNO) increased in patients with systemic sclerosis (SSc) and interstitial lung disease. Reactive oxygen species (ROS) and bleomycin induced skin and lung fibrosis in mice, mimicking the SSc in humans. Objectives: This study aimed to evaluate eNO measurement method in mice and to study the evolution of lung inflammatory and fibrotic processes in mice injected with HOCl or bleomycin.

Methods: C57BL/6 mice were randomized into 3 groups receiving subcutaneous injections of HOCl, bleomycin, or PBS for 2, 4, or 6 weeks. Exhaled NO was measured at the end of each injection period and after 2 resting weeks without injection (8 weeks). Mice were then sacrificed to obtain skin and lungs tissues for NO synthases (NOS) expression analysis.

Results: Increased exhaled NO, inducible NOS and 3-nitrotyrosine expression in bronchial epithelium, lung neutrophils and macrophages were observed at early phases (2 and 4 weeks) in HOCl- and bleomycin treated mice, mimicking the SSc in humans.

Conclusions: Exhaled NO can be used as a sensitive biomarker of lung inflammation in these murine models in which inflammation precedes fibrotic processes in skin and lungs. Mechanisms linking inflammation and fibrosis remain to be clarified.

Abstract printing supported by Chiesi Visit Chiesi at Stand B2.10

114s
P706
Elevated serum B cell activating factor belonging to the TNF family (BAFF) in interstitial lung diseases associated with collagen vascular disease

Tsunade Inokuma, Samukawa Takuya, Keiko Matsuno, Ikkei Higashimoto, Hiromasa Imae. Department of Pulmonary Medicine Advanced Therapeutics

Background: BAFF is a vital homostatic cytokine for B cells. Increased serum levels of BAFF were found in a number of different autoimmune diseases and patients with polymyositis with interstitial lung disease (ILD) had higher BAFF levels than those without ILD. However, serum BAFF levels have not been reported in patients with ILD associated with collagen vascular disease (CVD-IP) and idiopathic interstitial pneumonia (IIP).

Aim: We investigated serum levels of BAFF in patients with CVD-IP and with IIP to determine whether they correlate with pulmonary function.

Methods: Twenty-seven patients with IIP (n=15) and CVD-IP (n=12), who visited our institution from 2008 to 2010 and underwent pulmonary function test, were enrolled. Underlying CVDs consisted of rheumatoid arthritis (n=4), dermatomyositis (n=3), systemic sclerosis (n=2), ANCA-associated systemic vasculitis (n=1), and mixed connective tissue disease (n=1). Twenty-three healthy volunteers were included as a control group. Serum BAFF levels were measured by ELISA.

Results: Serum BAFF levels were 4.4±1.2 ng/ml for CVD-IP, 3.1±0.6 ng/ml for IIP, and 2.0±0.8 ng/ml for the control. BAFF was significantly elevated in CVD-IP compared with control subjects. An inverse relationship between serum BAFF levels and DLco was noted in patients with CVD-IP.

Conclusion: We found elevated serum BAFF levels in CVD-IP patients and correlation with severity for ILD.

P707
Grape seed proanthocyanidin extract (GSPE) attenuates bleomycin-induced pulmonary fibrosis in the mice

Seung Min Kim*, Bynuqul Kosworn*, Hong Rae Cho*, Young Ju Min*, Kwang Won Seo*, Yangjin Jegal1, Hee Jeong Cha*, Jung Soo Ahn1

1Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea; 2Biological Sciences, Biomedical Research Center, University of Ulsan, Ulsan, Republic of Korea; 3Surgery, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea; 4Pathology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea; 5Pulmonary and Critical Care Medicine, Presbyterian Medical Center, Jeonja, Republic of Korea

Background: Grape seed proanthocyanidin extract (GSPE) has more powerful antioxidative activity than other well-known antioxidants, including vitamin C and E. Idiopathic pulmonary fibrosis is a chronic progressive disorder with a poor prognosis. An antioxidant-antioxidant imbalance may contribute to the process of idiopathic pulmonary fibrosis.

Objectives: To examine whether GSPE which is known to act as an antioxidant has therapeutic effect on bleomycin-induced pulmonary fibrosis in mice, an animal model of idiopathic pulmonary fibrosis.

Methods: Mice were treated by intratracheal instillation of bleomycin. GSPE was administrated by intraperitoneal (IP) injections (30, 60, or 90 mg/kg). Mice were sacrificed on days 21 after bleomycin instillation.

Results: Compared with the BLM/Veh group, histologic findings in mice treated with BLM and IP injection of GSPE (BLM/GSPE) showed less fibrotic lesions in a dose-dependent manner. The mean Aschcroft’s fibrosis score in the BLM/Veh group was significantly higher than in the BLM/GSPE group.

Conclusions: GSPE attenuated bleomycin-induced pulmonary fibrosis in mice, suggesting that GSPE may be useful in the treatment of idiopathic pulmonary fibrosis.

P708
Clinical impact of irradiated lung volumetric modeling in adjuvant breast radiotherapy (RT)

Abhay Javia1, Sateesh Patel2, Rajiv Palival, Purvesh Patel1, Desheza Patel1

1Pulmonary Medicine, I.D.U. Medical College, Rajkot, Gujarat, India; 2Pulmonary Medicine, Pramukhswami Medical College, Karamsad, Gujarat, India; Dept. of Anaesthesiology, Pramukhswami Medical College, Karamsad, Gujarat, India

Objectives: To prospectively evaluate the lung dose-volume histogram (DVH) data in adjuvant breast RT, deduce the % irradiated volume (PIV) from 2-D parameters and analyze clinical impact with PFT & HRCT.

Methods: Patients (Pt) beginning breast RT between June ‘07 & March ‘10 were prospectively reviewed. Pt included were women with DCIS or Stage I–III carcinoma, who received RT using a 3D-CRT technique to the breast or chest wall. Lung DVH parameters, 2D parameters are reported. Post RT all Pt underwent 3 monthly (mo) clinical/PFT & 6 moly HRCT scan. Modeling equations to predict the PIV from 2D parameters were developed using multivariate linear regression analysis. Mann-Whitney U test was used to analyze PFT & HRCT changes over time. Binary logistic regression used to evaluate relation between PIV and Radiation pneumonitis (RP).

Results: 44 Pt met the inclusion criteria; 6 had 2FRT & 38 had 4FRT. With a median follow-up of 14 months, 3 Pt reported mild respiratory symptoms at 1mo, which resolved completely at 3mo post-RT. A significant decrease of FVC, FEVI, MMFE25-75 & DLco was observed at 3mo, with partial recovery at 9mo in the Pt treated with 4FRT, but there was no decrease of PFT in Pt treated with 2FRT. In HRCT at 6mo grade I opacity was present in 4 & 1 Pt(s) (PIV 15-19.9 and Mean lung dose 10.1±1.5) undergoing 4FRT & 2FRT.

Conclusions: Within the range evaluated in this study, the 3D parameters (FIV) better predicted an early decrease in pulmonary function, although HRCT detected RP was observed only when > 11% of the lung was irradiated in 4FRT-4FRT is associated with significant reduction in PFT but not 2FRT.

P709
Impact of diagnostic pitfalls on the management of pulmonary sarcoidosis
Ilya Sivkovskii1, Olga Lovacheva2, Eugene Shmelev3, Natalya Makaryants4

1Granulomatosis Diseases/Endoscopy Dept, CHU CAMBAS, Moscow, Russian Federation

Background: Work-up in patients with sarcoidosis includes differentiation mainly with pulmonary TB, hypersensitivity pneumonitis and community-acquired pneumonia. Usually bronchoscopy is performed with lung biopsy and BAL, but often this option is not available, and thus diagnostic mistakes arise.

Aim: To evaluate frequency and possible impact of diagnostic pitfalls on management of sarcoidosis patients.

Materials: 127 patients with newly diagnosed sarcoidosis based on results of lung biopsy and BAL during bronchoscopy were enrolled into study. We analyzed primary diagnosis and treatment, duration of treatment, age, sex, usage of systemic steroids after the final diagnosis and mean dose of them in patients with correct (controls) and incorrect primary diagnosis (study group).

Results: 23 patients (18.1%) had diagnostic pitfalls, from them 12 were treated with systemic pulmonary TB in HRZE regimen around a year (46.57±3.32 wks), 7 treated from pneumonia for 3.11±1.13 wks with further observation for 20.33±5.52 wks, and 4 pts were diagnosed as having a hypersensitivity pneumonitis with mean treatment with steroids 4.5±2.95±2.84 g. Groups were comparable for sex and age in study. In group, 10/23 (43.5%) pts had relapse of disease versus 30/104 (28.8%) in controls (p<0.05), frequency of systemic steroids use was also higher (15/23 (65.2%) versus 59/104 (56.7%) in controls). The mean dose of prednisone in study group was significantly higher than in controls: 21.7±0.9 mg vs 17.2±4.07 mg (p<0.05).

Conclusions: Diagnostic pitfalls in work-up process among sarcoidosis patients are quite frequent, and lead to a more severe disease flow with higher frequency of systemic steroids usage and higher dose of them.

P710
Pulmonary hypertension in different interstitial lung diseases
Liu Xiaoying, Wang Zao-yang, Hospital, Capital Medical University, Beijing, China

Background: Pulmonary Hypertension (PH) has been proposed a higher incidence in Interstitial Lung Diseases (ILDs). PH in different ILDs has different pathogenesis. PH in patients with ILDs is not well recognized and can occur in the absence of advanced pulmonary dysfunction or hypoxemia.

Objective: To investigate the incidence of pulmonary hypertension in different types of interstitial lung diseases.

Methods: Two hundred and five patients with ILD between 24 and 89 years old (mean age one hundred and four male, one hundred and one female) were evaluated, to discuss the incidence with different primary diseases, age and gender. ILD was diagnosed according to ATS/ERS classification standards in 2002, and according to ESCERS Guidelines in 2009, PH was diagnosed when SPAP of > 50mmHg was measured by UCG.

Results: Two hundred and five ILDs in Beijing Chao-Yang Hospital, ranging from January 1st 2010 to June 8th 2011, 27 were diagnosed as PH, so the incidence of PH in ILD is 13.2%. There was no significant difference of the incidence of PH in ILD between males and females (p=0.901). There was a significant difference of the incidence of PH in ILD between age > 60ys and < 60ys (p=0.017).The incidence of PH has no statistically significant difference among different types of ILD (p=0.455).

Conclusion: The total incidence of PH in ILDs is 13.2%, the patients with age ≥60y have higher incidence of PH. Whether PH develops in ILD seems to have no relation with the ILD types.
PT11
Profile of interstitial lung diseases in Pakistan, Karachi pulmonology clinics registry data, 2008 – 11
Mosavir Ansarie1,2, Asif Naseem1, Rashid Ahmed1, Azeemuddin Mahmood1,
1Pulmonology, Laiguat National Postgraduate Medical Centre, Karachi, Pakistan; 2Pulmonology, Health Care Hospital, Karachi, Pakistan; 3Radiology, Advance Radiology Clinics, Karachi, Pakistan; 4Radiology, Aga Khan University Hospital, Karachi, Pakistan

Background & Objective: No published data is available about the status of Interstitial Lung Diseases (ILD) in Pakistan. This study ponders to determine the incidence and relative frequency of various ILDs in Karachi, its most populous multi-ethnic city.

Methods: We reviewed data from a registry catering to 3 pulmonology clinics in different areas of the city. Based on a detailed questionnaire it records age, gender, exposure history, clinical presentation, HRCT and PFT findings mandatorily and BAL/VATS data if available. It prospectively recorded diagnosed ILD cases between Jan 2008 and Dec 2011 and deaths occurring during follow-up.

Results: In a total of 5600 pulmonology referrals, the incidence of ILD was 2.3% (n=133) with a mean age of 55.1 years (+12.9 SD), mortality of 22.6% and median survival of 3 years. Idiopathic Pulmonary Fibrosis (IPF) (49.6%), Non Specific Interstitial Pneumonitis (NSIP) (19.3%) and Sarcoidosis (17.3%) were the most frequent ILDs followed by Collagen Vascular Disease Related (5.3%), Drug Induced ILD (4.5%) and Hypersensitivity Pneumonitis (3.8%). Reporting females (n=91) outnumbered males (n=42). The incidence of IPF/NSIP was greater in males (76%) while sarcoidosis and other ILDs occurred more in females (34%). Interestingly, out of 45 IPF diagnosed housewives living in congested areas, 42% had chronic avian exposure due to home breeding/pets.

Conclusions: Establishes for the first time the considerable presence of ILD in Pakistani population and describes its salient features. Hopefully this will improve disease awareness and help us expand this registry to other major cities for greater input towards research.

P712
BAL protein profiles specific of different interstitial lung diseases
Elena Bargell1, Claudia Landi1, David Bennett1, Pasquale Di Sipio1, Luca Bini1, Paola Rotelli1,
1Respiratory Disease Sect., Dept. of Clinical Medicine and Immunological Science, University of Siena, Italy; 2Functional Proteomic Lab., Dept. of Biotechnology, University of Siena, Italy

Interstitial lung diseases (ILD) are an heterogeneous group of lung disorders with different etiopathogenesis, clinical courses and prognosis. In the last ten years our group of research is focusing on the proteomic analysis of BAL in different interstitial lung diseases.

Aims of this proteomic study were to compare protein profiles of Sarcoidosis (S), Idiopathic Pulmonary Fibrosis (IPF), Langerhans cell Histiocytosis (PLCH), pulmonary fibrosis associated with Systemic sclerosis (SSc) patients in order to identify proteins of interest involved in specific pathogenetic networks or potential biomarkers with clinical value.

Methods: Population of patients was composed by 9 S, 7 IPF, 9 PLCH, 7 SSc. Proteomic analysis was performed by 2D-electrophoresis. Image analysis was done by Image Master Platinum 7.0 software. Protein identification was performed by mass spectrometry.

Results: Image analysis revealed distinct expression profiles for each ILD. Among the 50 patients studied, in our ILD samples there were: Complex C3, complement factor B, complement factor I, antithrombin III, angiotensinogen, vitamin D binding protein, Leucin-rich alpha-2-glycoprotein, 14-3-3 protein epsilon, calcyphosin, kininogen N-term, alpha-2-HS-glycoprotein.

Conclusion: The proteomic analysis of BAL confirmed the possibility to use 2D-electrophoresis to highlight different protein profiles among specific ILDs.

PT13
Idiopathic pulmonary fibrosis: Clinical, radiological and functional significance of biomarkers of proliferation
Edwin Roger Parra, Marcel Lekevicius Costardi, Vera Capeolozzi, Pathology,
Faculdade de Medicina da Universidade de São Paulo, Brazil

Background: Natural course of idiopathic pulmonary fibrosis (IPF) could be predicted by proliferative markers of the fibrotic process, such as myofibroblasts and interleukins (IL)-13 and IL-14. Our primary aim was to determine whether these proliferative markers influence the course of IPF course measured by a clinical and functional score.

Methods: Twenty-eight patients with biopsy-proven IPF disease, who underwent pulmonary evaluation by high-resolution computed tomography (HRCT) fibrosis score and pulmonary function tests were studied. Five normal lung tissues (NLT) were included Biomarkers in lung tissues were detected by immunohistochemistry and quantified by histomorphometry for myofibroblasts alpha-smooth muscle actin (α-SMA), anti-interleukin (IL)-4 and IL-13.

Results: Myofibroblast amount, IL-4 and IL-13 expression were higher in IPF than in NLT (p<0.01). Myofibroblast expression of α-SMA was positively correlated to IL-14 and IL-13 expression. Lung tissue from patients with high HRCT fibrosis scores expressed significantly greater α-SMA+, IL-4 and IL-13 when compared with patients with low HRCT fibrosis scores (p<0.05). Negative correlations were found between myofibroblasts α-SMA+ and VC and DLCO.

Conclusions: Proliferative markers, detected by immunohistochemistry, in lung tissue allowed recognizing a dichotomous distribution of HRCT fibrosis course and influenced pulmonary function tests, suggesting that they may be promising markers of prognosis in these patients.

Financial support: FAPESP, CNPq.

PT14
Significance of protein S in patients with interstitial lung disease
Masahiro Naito1, Osamu Taguchi1, Kentaro Fujiwara1, Masahiro Onishi1,
Takehiro Takagi1, Tetsu Kobayashi1, Hiroyasu Kobayashi1, Toru Takamori1, Osa A, D' Alessandro-Gabarra1, Esteban Gabarra1,
1Department of Respiratory Division, Mie University School of Medicine, Tsu, Japan; 2Department of Immunology, Mie University Graduate School of Medicine, Tsu, Japan

Background: Protein S exerts anticoagulant activity by acting as a cofactor of activated protein C for the inactivation of coagulation factors Va and Vila. We have previously reported that protein S protects against lipopolysaccharides-induced acute lung injury by directly inhibiting the local expression of inflammatory cytokines without affecting coagulation (Takagi T, et al. 2009). However, the role of protein S in interstitial lung disease remains unclear.

Objective: The aim of this study is to evaluate the clinical significance of protein S in patients with interstitial lung disease.

Methods: This study comprised 106 patients with interstitial lung disease admitted to our institution between August 2008 and December 2011. There were 39 patients with interstitial pneumonia, 25 with sarcoidosis, 9 with collagen vascular disease-associated interstitial lung disease, 8 with organizing pneumonia, 7 with Nonspecific interstitial pneumonia, 5 with tumor-associated lung disease, 4 with hypersensitivity pneumonitis, 2 with IgG4 related multi-organ lymphoproliferative syndrome, 1 with alveolar proteinosis, and 1 patient with alveolar hemorrhage. Levels of protein S in BALF were measured using an enzyme-linked immunosorbent assay.

Results: Significant changes in the BALF levels of protein S were observed among the different types of interstitial lung diseases. The BALF level of protein S was significantly correlated with the number of macrophages, lymphocytes and with the BALF concentration of total protein and albumin.

Conclusion: These results suggest that protein S plays role in the pathogenesis of interstitial lung disease.

PT15
Combined pulmonary fibrosis and emphysema syndrome (CPFE)
Francisco Mutis1, Inmaculada Herráez2, Elena Bolló1, Silvia Fernández3, Beatriz Cartron1,
Emilio Santalla1, Florentino Diez1, Respiratory Department, Complejo Asistencial Universitario de León, León, Spain; 2Respiratory Department, Complejo Asistencial Universitario de León, León, Spain

Introduction: CPFE is a clinic entity which consists in the coexistence of emphysema of the upper lobes and pulmonary fibrosis of the lower lobes.

Method: Retrospective descriptive study of cases diagnosed of CPFE between 2007 and 2012.

Results: 44 patients, all of them men, with an average age of 69 years. All were current or ex smokers. 50% had a UIP (usual interstitial pneumonia) pattern at the HRCT, 11.4% possible UIP pattern, and 38.6% inconsistent UIP pattern. All the patients studied expressed in our ILD samples there were: Complex C3, complement factor B, complement factor I, antithrombin III, angiotensinogen, vitamin D binding protein, Leucin-rich alpha-2-glycoprotein, 14-3-3 protein epsilon, calcyphosin, kininogen N-term, alpha-2-HS-glycoprotein.

Conclusion: The aim of this study is to evaluate the clinical significance of protein S in patients with interstitial lung disease.

Table 1. Results

<table>
<thead>
<tr>
<th>Age</th>
<th>M/F</th>
<th>Current smokers</th>
<th>Ex-smokers</th>
<th>PAH</th>
</tr>
</thead>
<tbody>
<tr>
<td>44</td>
<td>49:12</td>
<td>43-83</td>
<td>65.9%</td>
<td>22.7%</td>
</tr>
<tr>
<td>44</td>
<td>100%</td>
<td>34.1%</td>
<td>29</td>
<td>10</td>
</tr>
<tr>
<td>15</td>
<td>38</td>
<td>22,8 (19,2–104,1)</td>
<td>17,1 (36–90)</td>
<td>58</td>
</tr>
<tr>
<td>29</td>
<td>65.9%</td>
<td>940,9 (1600–5820)</td>
<td>23,1 (45,1–139,7)</td>
<td>10</td>
</tr>
<tr>
<td>20</td>
<td>45–97,8</td>
<td>21,3 (47,3–152,5)</td>
<td>12,5 (45–97,8)</td>
<td>10</td>
</tr>
<tr>
<td>20</td>
<td>34,1%</td>
<td>96,0 (23,1–139,7)</td>
<td>25,7 (67–1340–4070)</td>
<td>10</td>
</tr>
<tr>
<td>20</td>
<td>65.9%</td>
<td>3514,2 (940,9–1600–5820)</td>
<td>101,7 (71,2–139,7)</td>
<td>10</td>
</tr>
</tbody>
</table>

Conclusions: All of the patients from this study are men with smoking history. These patients have, lung volumes preserved with a severe impairment of gas exchange. The high prevalence of PAH and its important role in the prognosis justify echocardiography. As these patients might have a high prevalence of lung cancer, a close follow-up would be advisable.
PT16
Nine cases of interstitial lung disease associated with anti-CADM140 antibody positive dermatomyositis
Yuko Wang1, Hatsuki Iwahashi1, Satoshi Watanebe1, Ryo Matsunuma1, Kanako Inuzuka1, Yukari Ikichikawa1, Nobuyuki Kato1, Masahide Yasui2, Kazuo Kanashita1, Masaki Fujimura1, Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; 2Respiratory Medicine, Kanazawa Municipal Hospital, Kanazawa, Ishikawa, Japan

Background: Anti-CADM140 antibody (CADM) was found in some amyopathic dermatomyositis (DM) patients (pts) in 2005. It was reported that about 50% of CADM positive pts died from acute exacerbation (AE) of DM-related interstitial lung disease (DM-ILD) despite treatment. As compared with CADM negative pts (about 6%), the rate of AE of ILD is clearly high in CADM positive pts. [Objective] To elucidate the clinical characteristics of ILD associated with CADM positive DM.

Methods: Blood examination, arterial blood gas analysis, pulmonary function testing, bronchoalveolar lavage (BAL) analysis and pattern of chest CT were examined in 9 pts who were diagnosed with CADM positive DM in our hospital.

Results: Since the average value of the FeNO and CRP at the time of the first medical examination was 6620±1 and 0.56 mg/dl, we thought that inflammation was slight. The value of CK was in the normal range in 7 pts, slightly high (217 IU/l) in 1, and significantly high (26300 IU/l) in 1. The value of KL-6 was in the nearly cut-off range in 8 pts, and significantly high in 1 (3764). Alveolar-arterial oxygen difference was increased in 3 pts. In 4 pts in which BAL was performed, the lymphocyte differentiation was all high. Concerning chest CT image, patchy shadow or patchy shadow and tuberclar shadow in outside layer of the lung field were seen in 7 pts, GGO around broncho-vascular bundle in 1, and no abnormal shadow in 1. All of the shade were slight. Although one pt died of AE, 8 pts survive as of February, 2012.

Conclusion: In DM-ILD, even if the CT image and data are slight, whenever the CT image is not typical NSIP pattern, we have to take the possibility of CADM into consideration.

PT17
Chitotriosidase activity and CHIT1 gene polymorphism in sarcoidosis
Matevž Harlandič1, Mirjana Zapancic2, Barbara Salobir1, Aleš Mayer1, Boris Peterlin3, Marijeta Tercelj1,1Department of Pulmonary Diseases, University Medical Center, Ljubljana, Slovenia; 4Biochemical Laboratory, Pediatric Clinic, University Medical Centre, Ljubljana, Slovenia; 5Institute for Medical Genetics, Medical Faculty Ljubljana, Ljubljana, Slovenia

Introduction: Among several biomarkers of sarcoidosis activity chitotriosidase (CTO) has been found to be useful. Some subjects have a 24-base pair duplication in the CTO gene (CHIT1) that results in the production of inactive enzyme which might be associated with the activity of the medication.

Aims: The study was conducted 1) to confirm previous observations of increased CTO activity in patients with sarcoidosis and 2) to evaluate influence of CHIT1 polymorphism on CTO activity.

Methods: The study comprises 47 patients with newly diagnosed active sarcoidosis (32 females, average age 42.3 years). CTO activity was determined in serum and BAL using a standard fluorimetric method. CHIT1 genotyping was done by polymerase chain reaction (PCR).

Results: A normal CHIT1 genotype (NN) was present in 61.5% of the subjects, 34.0% were heterozygotes for defective allele (ND) and 4.0% were homozygotes for defective allele (DD). The mean serum CTO value was 736 nmol/mL/h (± 383) and was increased in 93.6% of patients. The mean BAL CTO value was 9.01 nmol/mL/h (± 12.8). There was a correlation between serum and BAL CTO activities (r 0.710, p < 0.001).

There was no significant difference between NN and ND subjects in serum CTO activity (855±657 nmol/mL/h, 612±348 nmol/mL/h, p 0.331), but a significant difference in BAL CTO activity (12.2±4.15.02 mmol/mL/h, 4.31±4.57 mmol/mL/h, p=0.003). There was no CTO activity in mutation homozygotes.

Conclusions: The results confirm previous observations that the CTO activity is increased in patients with sarcoidosis. Unexpectedly, there was no significant difference in serum CTO activity between CHIT1 normal homozygotes and heterozygotes which warrants further study.

PT18
Safety and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) receiving commonly used concomitant medications
Paul Noble1, Steven Sahn2, Dominique Valeyre3, Roland du Bois4, 1Department of Clinical and Biological Sciences, University of Turin, Italy; 2Clinical Research, InterMune, Inc., Brisbane, CA, United States; 3Pneumologie/Allergologie, Rubrlandklinik, Essen, Germany; 4Department of Medicine, University of California San Francisco, United States

Background: The CAPACITY Program (CAP) included two Phase 3 trials of PFD in 779 patients with IPF. Analyses were conducted to assess the safety of PFD in patients receiving commonly used concomitant medications.

Objective: Evaluate the safety/tolerability of PFD in IPF patients receiving commonly used concomitant medications.

Methods: Pooled data from the CAP trials were analyzed. Commonly used concomitant medications were defined as those used by ≥25% of patients in any treatment group between the first and last dose of study drug. The percentage of patients with selected treatment emergent adverse events (TEAEs) while on or within 28 d of cessation of commonly used concomitant medications was assessed. Patients in the PFD 2403 mg/d group were evaluated using a composite safety endpoint that included any Grade 3 or 4 TEAE, discontinuation of PFD, interruption/dose reduction of PFD, or any TE serious AE.

Results: Commonly used concomitant medications and vaccines included: acetylsalicylic acid, azithromycin, influenza vaccine, multivitamins, omeprozole, paracetamol, salbutamol, and simvastatin. No evidence of a clinical pattern of TEAEs was observed with the use of PFD and these commonly used medications or vaccines. Patients receiving these agents were no more likely to meet the composite safety endpoint than those not receiving a commonly used concomitant agent.

Conclusions: These data suggest that PFD is safe and generally well tolerated in patients with IPF when used with a spectrum of common medications. More long-term data will be collected in RECAP, an open-label extension trial evaluating PFD in patients with IPF.

P719
Systemic lupus erythematosus (SLE): Cyto- and chemokines as possible serum markers for pulmonary involvement?
Johannes Streitze1, Zsofia Weiszhar1, Christine Balogh1, Andras Bikov, Krisztina Vincze1, Lilla Tamasi2, Ilidiko Horvath3, Veronika Muller3, Department of Pulmonology, Semmelweis University, Budapest, Hungary

SLE is a systemic autoimmune disease associated with high prevalence of lung involvement. Pulmonary manifestations (PM) in SLE are difficult to diagnose and the ability of its detection with serum markers could be useful for early detection and specific treatment. Twenty three patients with SLE (age: 45.4±14.6 years; 22 female, 10 smokers) were enrolled in pulmonary examination including chest X-ray, lung function test, CO diffusion capacity (DLCO) measurement and blood gas analysis. Plasma of 17 patients was analyzed by protein array system with chemiluminescence imaging, including the cytokines and chemokines: 4-1BB, IP-10, IL-12, IL-20, IL-17, CCL4, CCL2, CCL28, MCP-1, MCP-4, IFN-γ.

PM was diagnosed in 12 patients (52.2%; age:41.3±14.2 years), including pulmonary fibrosis (3), shrinking lung syndrome (1) and ventilatory disorder (8). Eleven patients had no PM (47.8%; age:50.0±21.2 years). In patients with PM significant decrease of static lung volumes and DLCO were noted (TLC % pred: 81.3±3.4 vs. 93.7±3.9; p<0.05; FEV1% pred: 78.6±5.7 vs. 94.2±5.5; p=0.05; DLCO %: 46.0±4.4 vs. 97.3±7.3; p<0.001). Microarray measurements confirmed significantly higher CCL21 level in SLE patients with PM, negatively correlating with FEV1 (r=-0.65, p=0.04) and positively with resistance of the airways (r=0.73, p=0.02). The biomarkers MCP-1 and IP-10 were above the detection limit in all patients and higher levels were detected in SLE patients with PM. In lupus patients PMs are prevalent and are associated with decreased lung volumes and DLCO. Microarray results identified CCL21 and MCP1, IP10 as potential candidates for further analysis of PM in SLE patients.